Background: In spite of the technological advances in dental restoratives, there is
a constant need for the development of a novel biologically-based autologous capping substitute that overcomes the side effects of various synthetic-based biomaterials used for pulpotomies.
Purpose: To evaluate clinically and radiographically the success of platelet-rich plasma (PRP) medicament in primary molars pulpotomy.
Materials and methods: A randomized controlled clinical trial in which 20 children aged 5-8 years were selected. Each child had at least two lower deeply carious primary molars (1st and/or 2nd) indicated for pulpotomy and randomly divided into two groups; The PRP (study group) in one quadrant and formocresol (control group) in the opposite one. All teeth were treated with the same conventional and standard pulpotomy technique. All patients were followed up clinically and radiographically at 3, 6, 9 and 12 months post-operative. Data were statistically analyzed using Fisher exact test.
Results: The clinical and radiographic success showed no statistically significant difference between both groups (p > 0.05). The overall clinical success rate of pulpotomized teeth at the end of recall time was 100 % for PRP and 90% for FC group, whereas the overall radiographic success was 90% for PRP and 85% for FC group.
Conclusion: From the present study, it was concluded that PRP had a successful outcome,
a potent therapeutic medicament and had a promising alternative to the presently used pulpotomy medicament.